Related Experiment Video
Updated: Jul 13, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
The power and limitations of pharmacogenetic epidemiology
Kate Lapane1, Martin A Weinstock
1Brown Medical School-Community Health, Providence, Rhode Island 02912, USA. Kate_Lapane@brown.edu
Abstract:
Ovid and many physicians in the thousands of years since have been stymied by the large interindividual variability in drug response and toxicity. That all patients do not reap the same benefits from the same drugs is well established. In the case of statins, estimates of effectiveness range from 30 to 70% of users (Spear et al., 2001). Disentangling why this occurs is complex, and two new disciplines are likely to make headway in furthering our understanding of these phenomena.
Related Concept Videos
Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics of Drug Metabolism: Overview
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Principles of Pharmacogenetics: Types of Genetic Variants
Pharmacogenomics: Identification of New Drug Targets
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes